Trial intelligence / Profile preview

SSG XX Protocol for High-Risk Soft Tissue Sarcoma

NCT00790244Phase 2Unknown

Sponsor
Oslo University Hospital
Start
Oct 2007
Primary completion
Oct 2012
Modality
DNA Intercalators/Alkylators
Countries
1
01

Overview

A Phase 2 trial of doxorubicin, ifosfamide in soft tissue sarcoma (STS), sponsored by Oslo University Hospital. Status: unknown.

02

Drugs

doxorubicinifosfamide
03

Conditions

soft tissue sarcoma (STS)

Beyond the preview

Go deeper on NCT00790244.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00790244.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call